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INTRODUCTION
Neuromuscular disorders are a heterogeneous group of genetic
diseases that cause a progressive loss of motor ability. There are
more than 30 recognized genetically defined forms of
neuromuscular disorder, and mutations in many genes causing
deficiency or loss of function of different important muscle proteins
have been reported as their cause. For instance, defects in
components of the dystrophin-glycoprotein complex (DGC) are
known to cause Duchenne muscular dystrophy (DMD),
sarcoglycanopathies and some forms of congenital muscular
dystrophy (Ervasti and Campbell, 1993; Yoshida and Ozawa, 1990).
The DGC is an oligomeric complex composed of dystrophin,
sarcoglycans, dystroglycans, sarcospan, syntrophins and α-
dystrobrevin. It acts as a link between the cytoskeleton of the muscle
cell and the extracellular matrix, providing mechanical support to
the plasma membrane during myofiber contraction. Beside this
structural function, the complex might also play a role in cellular
communication (Campbell and Kahl, 1989; Cohn and Campbell,
2000; Rando, 2001). DMD is caused by mutations in the gene that
encodes dystrophin (Hoffman et al., 1987), a protein that is linked
through its N-terminal domain to actin and through its C-terminal
domain to the integral membrane protein β-dystroglycan (β-DG).
The peripheral membrane glycoprotein α-dystroglycan (α-DG), a
receptor for the heterotrimeric basement membrane protein
laminin-2, binds to β-DG and so completes the connection between
intracellular proteins and the extracellular matrix (Straub and
Campbell, 1997).
Some forms of muscular dystrophy are associated with genes
encoding putative or known glycosyltransferases that are
responsible for the appropriate glycosylation of α-DG. Therefore,
the importance of post-translational modifications of muscle cell
proteins for normal muscle function, in particular α-DG, has
become increasingly clear.
Analysis of mouse models for neuromuscular diseases has
unraveled previously unknown pathogenetic mechanisms for the
development of muscular dystrophy. These animals generally
present alterations that are frequently observed in humans with
the disease and are therefore important tools for genetic, clinic and
histopathological studies, and provide important clues for
understanding the pathogenesis of these disorders. Animal models
are also very valuable for testing potential therapeutic approaches.
The Dmdmdx mouse is a naturally occurring mutant for DMD, with
a stop codon in exon 23 of the murine dystrophin gene. These mice
have no detectable dystrophin in the muscle, except in rare
revertant myofibers (Hoffman et al., 1987; Bulfield et al., 1984;
Sicinski et al., 1989). However, Dmdmdx mice show a mild
phenotype, with comparatively moderate muscle pathology, and
muscle degeneration is followed by a large amount of regeneration
(Dangain and Vrbova, 1984). Therefore, although the Dmdmdx
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SUMMARY
Although muscular dystrophies are among the most common human genetic disorders, there are few treatment options available. Animal models
have become increasingly important for testing new therapies prior to entering human clinical trials. The Dmdmdx mouse is the most widely used
animal model for Duchenne muscular dystrophy (DMD), presenting the same molecular and protein defect as seen in humans with the disease.
However, this mouse is not useful for clinical trials because of its very mild phenotype. The mouse model for congenital myodystrophy type 1D,
Largemyd, harbors a mutation in the glycosyltransferase Large gene and displays a severe phenotype. To help elucidate the role of the proteins
dystrophin and LARGE in the organization of the dystrophin-glycoprotein complex in muscle sarcolemma, we generated double-mutant mice for
the dystrophin and LARGE proteins. The new Dmdmdx/Largemyd mouse model is viable and shows a severe phenotype that is associated with the
lack of dystrophin in muscle. We tested the usefulness of our new mouse model for cell therapy by systemically injecting them with normal murine
mesenchymal adipose stem cells (mASCs). We verified that the mASCs were hosted in the dystrophic muscle. The new mouse model has proven to
be very useful for the study of several other therapies, because injected cells can be screened both through DNA and protein analysis. Study of its
substantial muscle weakness will also be very informative in the evaluation of functional benefits of these therapies.
Dmdmdx/Largemyd: a new mouse model of
neuromuscular diseases useful for studying
physiopathological mechanisms and testing therapies
Poliana C. M. Martins1, Danielle Ayub-Guerrieri1, Aurea B. Martins-Bach1, Paula Onofre-Oliveira1, Jackeline M. Malheiros2,
Alberto Tannus2, Paulo L. de Sousa3,4, Pierre G. Carlier3 and Mariz Vainzof1,*
RESEARCH ARTICLE
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
mouse is a good genetic and biochemical model for DMD, it is not
useful for functional evaluation in therapeutic trials.
The myodystrophy Largemyd mouse model harbors a mutation
in the gene Large, which encodes a glycosyltransferase that
presumably alters the glycosylation of α-DG. Mutations in the
human LARGE gene cause the severe form of muscular dystrophy,
congenital muscular dystrophy type 1D. Muscle protein analysis in
affected individuals shows hypoglycosylation of α-DG and a
consequent reduction of numerous ligand components of the
extracellular matrix, such as laminin-2 (Grewal et al., 2005).
Largemyd mutant mice develop a progressive myopathy, with a
maximum lifespan of 39 weeks.
Clinically, these animals show diffuse and progressive muscle
weakness, and widely distributed focal lesions in skeletal muscles
as early as 16 days of age. Muscle histopathology includes abnormal
muscle morphology, such as degeneration, loss of striation,
variation in fiber size and the presence of central nuclei. Several
targeted mouse models for DGC-associated muscular dystrophy
have been generated. Some double mutants using the Dmdmdx
background have also been created, exhibiting more severe
phenotypes (Megeney et al., 1996). These observations have
instigated the generation of genetically engineered mouse models
for DGC-linked muscular dystrophy.
To better understand the interplay between the lack of dystrophin
and LARGE glycosyltransferase in muscle function, we bred Dmdmdx
and Largemyd mice, generating double-mutant animals deficient in
these two proteins. In addition to the important physiopathological
aspects of the effects of these two mutations in muscle formation
and function, this model has an important application for testing
therapies, integrating functional, molecular and protein studies. The
new Dmdmdx/Largemyd mouse model has a severe phenotype that is
associated with the lack of dystrophin in the muscle. Therefore, it is
a good model for testing cell therapies, because injected cells can be
tracked both through DNA analysis for the wild-type allele of the
Large gene, as well as through the study of the presence of normal
dystrophin protein expressed by the injected cells. To test this
potential, we systemically injected normal murine adipose
mesenchymal stem cells (mASCs) into this new dystrophic model,
and we verified that the mASCs were hosted in the dystrophic muscle,
as detected by DNA analysis, and expressed traces of dystrophin.
These results could have important applications for future therapy
in patients with different forms of muscular dystrophy.
RESULTS
Generation of Dmdmdx/Largemyd mice
The breeding of a male Largemyd+/− with female Dmdmdx originated
52 animals in F1. The female:male ratio was 47:53, not significantly
different from the expected. All male progeny carried the Dmdmdx
mutation in the X chromosome, and were genotyped for the mutant
Large allele. Sixteen heterozygous Dmdmdx/Largemyd+/− male mutants
were identified (Fig. 1B) and backcrossed with female Dmdmdx mice.
In F2, we obtained 42 mice, 20 of which were Dmdmdx/Largemyd+/−
mutants (9 females and 11 males), that were cross-bred for generating
the Dmdmdx/Largemyd lineage in F3. We obtained a total of 100
newborn mice, with a frequency of each genotype in accordance with
mendelian expectations (25 homozygous Dmdmdx/Largemyd−/−, 22
wild-type Dmdmdx/Largemyd+/+ and 53 heterozygote Dmdmdx/
Largemyd+/−) (Fig. 1C).
Phenotypic characterization of the Dmdmdx/Largemyd mouse
The main features of double-mutant Dmdmdx/Largemyd mice were a
substantial delay in growth and development, and incapacity of
reproduction (Fig. 2). They are smaller at birth and have low
neonatal viability: only four among the 25 double mutants survived
after the first 24 hours. With the progression of the disease, the mice
showed an abnormal phenotype, with decreased body weight, a
hunched stance, severe contraction of hind limbs and a stiff walking
posture. Compared with the parental Largemyd lineage, the double
dmm.biologists.org1168
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TRANSLATIONAL IMPACT
Clinical issue
Although muscular dystrophies are among the most common human genetic
disorders, the treatments that are currently available are palliative rather than
curative. A notable member of this group of debilitating disorders is Duchenne
muscular dystrophy (DMD), which is caused by mutations in the gene that
encodes dystrophin, a key component of the dystrophin-glycoprotein complex
(DGC) that connects intracellular proteins with the extracellular matrix.
Dystroglycanopathies, another common group of muscular dystrophies, are
associated with aberrant glycosylation of α-dystroglycan, which is also an
important component of the DGC. The underlying mechanisms, however,
remain only partially characterized, and there is an increasing need to
establish effective animal models for mechanistic studies and drug screening.
The Dmdmdx mouse is the most widely used animal model for DMD; however,
these mice do not fully recapitulate the severity of the human disease. The
Largemyd mouse, which harbors a mutation in the glycosyltransferase gene
Large and presents with aberrant glycosylation, faithfully models congenital
muscular dystrophy type 1D. To date, these two models have only been
studied separately, which has not allowed the interplay between the
dystrophin and LARGE proteins to be investigated.
Results
To elucidate the roles of the proteins dystrophin and LARGE in the
organization of the DGC in the muscle sarcolemma, the authors generated a
double-mutant mouse for the two proteins. Their phenotypic characterization
of the Dmdmdx/Largemyd mouse model showed that the mice are viable, despite
displaying a developmental delay and infertility. Furthermore, the mice
exhibited progressive muscular weakness and functional defects. Overall, the
phenotype of the double mutant was shown to be more severe than that in
either of the parental lineages. Using protein immunohistochemical analysis,
the authors confirmed that the severe neuromuscular phenotype correlates
with a deficiency of dystrophin in muscle cells. The usefulness of the double-
mutant mouse model for testing cell therapy was determined by systemically
injecting the mice with normal murine adipose stem cells (mASCs). The mASCs
were appropriately hosted in the dystrophic muscle, and could be screened
both through DNA and protein analyses.
Implications and future directions
This study demonstrates for the first time that combining the genetic defects
associated with DMD and dystroglycanopathies does not cause embryonic
lethality. However, a deficiency in both the LARGE and dystrophin genes gives
rise to severe muscular weakness, indicating that the loss of dystrophin
together with aberrant glycosylation of α-dystroglycan is more deleterious for
muscle tissue than either of the defects in isolation. This novel double-mutant
mouse model accurately recapitulates the symptoms of human muscular
dystrophies and could be used for further studies of the mechanisms involved
in DGC destabilization. In addition, the mouse model has potential utility for
the study of stem cell replacement therapy, because injected stem cells can be
easily traced using DNA and protein analysis. Thus, the model could have
important applications for assessing the molecular effects and functional
benefits of forthcoming therapies in individuals with different types of
muscular dystrophy.
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mutant was weaker and had a reduced maximum lifespan of 24 weeks
(in contrast with Dmdmdx: up to 2 years; and Largemyd: 39 weeks at
most) (Lane et al., 1976). Additionally, severe bone alterations were
observed with time, and the double mutant developed severe
kyphosis. Radiological spinal column analyses at 120 days of age,
performed in one mouse from each strain, showed the most severe
degree of spinal curvature alteration, when compared with the
parental Dmdmdx and Largemyd lineages at the same age (Fig. 3A).
T2-weighted magnetic resonance images (MRIs) revealed regions
of hyper intensities in the calf muscles in the three lineages. Whereas
the Dmdmdx mouse presented a patchy pattern, with several hyper
intense points randomly distributed in the calf muscles, the Largemyd
mouse presented a hyper intense but homogeneous signal in the
posterior compartment, particularly in the soleus muscle. Visually,
the double-mutant Dmdmdx/Largemyd mouse tended to present a
combination of the patterns of the parental lineage: the overall
elevation of the muscle signal from the Largemyd model plus the
patchy pattern from the Dmdmdx model (Fig. 3B).
Functional assessment
Functional analysis, comparing Dmdmdx/Largemyd mice with the
more severely affected parental lineage Largemyd and the milder
Dmdmdx strain, showed that, overall, the double mutant presented
a worse performance in the test bar for the front legs (Fig. 4). The
differences were statistically significant at the ages of 30 days
(P=0.007), 60 days (P=0.03), 90 days (P=0.02) and 120 days (P=0.03).
After this age, both Dmdmdx/Largemyd and Largemyd lineages were
similarly impaired.
Histological and histochemical analyses
A comparative histopathological analysis of gastrocnemius muscle
of the three dystrophic lineages and the wild-type control is shown
Disease Models & Mechanisms 1169
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Fig. 1. Generation of the animal model Dmdmdx/Largemyd. (A)The breeding
program. L, wild-type Large allele; l, mutated Large allele. (B)The genotyping
methodology. The 421 bp band is the mutated allele, and the 162 bp band is
the wild-type allele of the Large gene. (C)The proportion of each genotype in
F3. 
Fig. 2. Phenotypic
characterization of the
Dmdmdx/Largemyd mouse.
(A)Growth and development
delay in the Dmdmdx/Largemyd
double mutant compared with
his brother Dmdmdx at different
ages (1, 7, 14 and 30 days).
(B)Animals at the age of 120
days.
Fig. 3. Image analyses of the Dmdmdx/Largemyc model. (A)Radiography of
the spine of the different models (Largemyd, Dmdmdx/Largemyd and Dmdmdx) at
the age of 120 days. (B)Axial T2 weighted MRI of 2-month-old Largemyd,
Dmdmdx/Largemyd and Dmdmdx mice, at the lower leg level. Solid arrows
indicate affected regions; dashed arrows indicate the position of the lower leg
bones, tibia and fibula. L, left side; R, right side.
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in Fig. 5. A similar pattern of muscle degeneration in both Largemyd
and Dmdmdx/Largemyd was observed in all ages, with variation in fiber
size, centrally located nuclei, degenerated fibers, and connective tissue
replacement. The Dmdmdx mice showed the typical pattern of high
regeneration, with almost all fibers centronucleated after the age of
3 months. Picrossirius staining showed a crescent amount of
connective tissue, from the Dmdmdx, Largemyd and Dmdmdx/Largemyd
mice. Protein immunohistochemical analysis revealed a total
deficiency of dystrophin in the Dmdmdx and the double
Dmdmdx/Largemyd mice, accompanied be secondary deficiency of
sarcoglycan proteins, as observed by anti-δ-sarcoglycan (δ-SG)
antibody. Interestingly, groups of revertant dystrophin-positive fibers
were also observed in the Dmdmdx/Largemyd mice, in the same
proportion observed routinely in the Dmdmdx mouse – about six to
ten groups of fibers in the whole section.
mASC therapy in double-mutant Dmdmdx/Largemyd mice
mASCs were used to assess the utility of the model for future
therapies because of their good myogenic potential (Zuk et al.,
2002). At 1 week after the last of the three injections, the tissues
were collected, and DNA analysis for the normal allele of the Large
gene identified the presence of the injected cells in the heart,
stomach, diaphragm, gastrocnemius muscle and quadriceps muscle
(Fig. 6A). Immunofluorescence analysis for dystrophin was negative
in the injected muscles (Fig.  6C), whereas western blot analysis
identified traces of the 427 kDa dystrophin band in the
gastrocnemius, quadriceps and heart muscles (Fig. 6B).
DISCUSSION
Both the organization and preservation of the proteins of the DGC
in the sarcolemma are essential for normal muscle function (Ervasti
and Campbell, 1993; Yoshida and Ozawa, 1990, Campbell and Kahl,
1989). Different studies have assessed the interaction of the proteins
forming the DGC, both in patients and animal models that mimic
human diseases (Vainzof et al., 2008).
The dystrophin protein acts as a link between the cytoskeleton
of the cell and the complex contractile machinery within the muscle
fiber. Individuals with dystrophin deficiency also have a secondary
deficiency in the proteins that make up the DGC (Ohlendieck and
Campbell, 1991; Cohn and Campbell, 2000). The LARGE protein
is involved in glycosylation pathways and, when altered, a reduction
in the molecular weight of α-DG (van Reeuwikj et al., 2007) and a
secondary decrease of the protein α-2-laminin are observed.
Therefore, both proteins, dystrophin and LARGE, participate in
the formation of the DGC. Changes in these proteins destabilize
the complex, causing a dystrophic phenotype.
The main goal for the generation of the Dmdmdx/Largemyd mouse
was to assess the pathological effects of hypoglycosylation in the
modulation of the dystrophic phenotype and to estimate the
impact caused by the absence of both dystrophin and LARGE
proteins in DGC formation.
The double mutant Dmdmdx/Largemyd is the first animal model
that combines both genetic defects found in DMD and
dystroglycanopathies. The first important information is that this
animal is viable, with no intrauterine death. Therefore, deficiencies
dmm.biologists.org1170
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Fig. 4. Functional analysis of the test bar in Largemyd, Dmdmdx/Largemyd and Dmdmdx mice. x-axis, days; y-axis, the mean time the mice from each group could
hold the bar (seconds). The table below the graph shows the mean time the mice from each group could hold the bar (seconds; X), the number of tested animals
(N) and the significance (P) in the Mann-Whitney test, comparing the two weaker strains, Dmdmdx/Largemyd versus Largemyd (*P<0.05, **P<0.01).
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of both dystrophin and LARGE proteins are compatible with life.
Accordingly, the double mutant showed greater weakness, when
compared with the Largemyd parental lineage, indicating that the
loss of dystrophin together with a defect of glycosylation of α-DG
is more deleterious for the muscle and worsens the phenotype.
Functional characteristics of  Dmdmdx/Largemyd mice
In the present study, we found that, among the 52 animals obtained
in F1, the proportion of females and males was similar, and 50% of
the Dmdmdx males also carried the Largemutation. This mendelian
proportion suggests that there are no deleterious effects for an
heterozygous Large mutation in the Dmdmdx phenotype. These
males were successfully cross-bred with female Dmdmdx mice,
indicating no reproductive impairment. In F3 we obtained double-
mutant animals in the mendelian ratio, demonstrating that the
absence of the two proteins did not interfere in the formation of
embryos, or in the formation of muscle during development.
However, among the total number of affected animals, only 15%
survived after the first 24 hours of life. The cause of death of these
animals was not clear, but some signs were observed, such as
Disease Models & Mechanisms 1171
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Fig. 5. H&E staining, picrossirius staining for collagens, and
immunohistochemical analysis for α2-laminin, dystrophin and
δ-SG in normal C57BL, Dmdmdx, Largemyd and Dmdmdx/Largemyd
mice aged 180 days. Magnification 200×.
Fig. 6. DNA screening and protein analyses in the Dmdmdx/Largemyd model. (A)DNA screening for the injected cells: PCR for the Large normal allele (162 bp) in
the injected mice. Animals 1 and 2 were injected with cells, and animal 3 with PBS. Columns: 1, heart; 2, gastrocnemius; 3, stomach; 4, quadriceps; 5, diaphragm;
6, tail. Positive control (162 bp) and molecular weight (MW) are shown. (B)Dystrophin western blot analysis from different muscles from the mASC-injected and
PBS-injected animals, reacted with antibody to dystrophin (H300, Santa Cruz Biotechnology, Inc.). Column 1, molecular weight; 2, normal human muscle; 3,
normal C57BL muscle. Muscles from Dmdmdx/Largemyd mouse 1: column 4, gastrocnemius; 5, quadriceps; 6, diaphragm; 7, heart; 8, stomach. Muscles from
Dmdmdx/Largemyd mouse 2: 9, gastrocnemius; 10, quadriceps; 11, diaphragm; 12, heart; 13, stomach. Muscles from Dmdmdx/Largemyd mouse 3: 14, quadriceps; 15,
diaphragm. (C)Dystrophin immunofluorescence analysis in a normal control and in one injected muscle: Dmdmdx/Largemyd mouse 2, muscle gastrocnemius.
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hypoxia, spasm and abrupt movements of the abdomen, suggesting
breathing difficulties in the first hours of life. Respiratory
impairment is a common problem in neuromuscular disorders,
although dystroglycanopathy generally does not include respiratory
distress (Godfrey et al., 2007). Additionally, the Largemyd mouse
does not show respiratory problems (Grewal et al., 2005).
Nonetheless, further studies will be carried out to assess lung
capacity of these animals soon after birth, to better understand the
cause of the perinatal death.
The most evident characteristic observed in Dmdmdx/Largemyd
animals when compared with their Dmdmdx littermates was their
significantly smaller size at birth, which remained smaller
throughout their development. By contrast, homozygous Largemyd
mice can only be recognized by the smaller size at the age of 12-
15 days, when they also present abnormal posturing of their hind
limbs (Grewal et al., 2005). This abnormal posture was observed
in the double mutants at the same age. Dmdmdx/Largemyd animals
that reached adulthood lived up to 24 weeks, which is a significantly
decreased lifespan when compared with the Largemyd model (39
weeks at most), Dmdmdx (2 years) and normal controls (2 years).
Additionally, the double mutant showed no ability to reproduce,
as is also the case for homozygous Largemyd mice. Additional aspects
of the phenotype in double mutants included thoracic kyphosis,
outward curvature of the spine and hunching of the back, which
was evident at 4 weeks and became progressively worse. This
alteration can be important for screening the success of therapies,
because X-ray measurement can be standardized and compared
with check evidence of amelioration of the phenotype. In the
homozygous Largemyd mouse, this feature is observed at 6-8 weeks
(Grewal and Hewitt, 2002). The observation of more severe features
in double mutants suggests that our new Dmdmdx/Largemyd mouse
model has a more substantial weakness than Largemyd mice.
By contrast, the MRI pattern of the double mutant Dmdmdx/
Largemyd showed characteristics of both parental lineages. The
hyperintensities observed in all three lineages were not related to fat
infiltration, because they were observable in the images with and
without fat suppression. This indicates that the hyperintensities seen
in the muscles of the three lineages were related to inflammation
and necrosis. Further studies are in progress to better characterize
the muscle involvement in these three mouse lineages using MRI.
Functional evaluation
Characteristically, young and adult mouse models with muscle
weakness, when suspended by the tail, tend to adduct the hind limbs
and flex the knee, ankle and toe joints, whereas wild-type mice
spread the hind limbs and extend the joints. This aberrant feature
was found in Dmdmdx/Largemyd mice, being the first observed sign
of weakness. To better understand muscle alterations in the
Dmdmdx/Largemyd mice, we compared its pattern of weakness with
the most affected parental lineage, Largemyd. Dmdmdx/Largemyd mice
presented a statistically significant worse performance in the bar
test for the front legs, up to the age of 120 days. After this age, both
lineages were equally severely affected. The test was also used for
the evaluation of the four legs, with the same poorer performance
of the Dmdmdx/Largemyd mice compared with Largemyd.
This test evaluates primarily the strength and endurance of these
limbs, and is also helpful in evaluating other strength parameters
such as balance, ability to use the tail to hold the bar and the use
of the rotation of the body to reach the bar (Krämer et al., 1998).
Therefore, in general, the new Dmdmdx/Largemyd model had a worse
performance in the bar for the front legs and four legs, when
compared with the Largemyd lineage, demonstrating a greater
weakness.
Histopathological analysis of inbred Dmdmdx, Dmdmdx/Largemyd and
Largemyd mice
For the evaluation of muscle histopathology involvement, we
performed morphological and protein analysis by comparing the
muscles of double-mutant animals with those from the parental
lineages, in different ages. In general, Dmdmdx/Largemyd mice
showed a similar pattern of degeneration as the Largemyd. However,
Dmdmdx/Largemyd mice presented a more severe pattern of
degeneration at the ages of 21 and 180 days. This included an
increase in perimysial and endomysial tissue, a larger variation in
fiber size, and an increased proportion of central nuclei and
splitted fibers.
The Dmdmdx mice showed no dystrophin in the muscle,
consistent with their genetic defect. Dmdmdx/Largemyd mice were
also deficient for dystrophin, confirming their genotype.
Interestingly, groups of revertant dystrophin-positive fibers were
also observed in this new Dmdmdx/Largemyd model. The mechanism
of revertant fibers has been widely described in the Dmdmdx mouse,
which has a frequency of about 2-3% of positive dystrophin fibers
in the muscle. These fibers are also routinely observed in individuals
with DMD, as well as in other models for DMD, such as dogs and
other mouse lineages with induced mutations in the Dmd gene
(Danko et al., 1992).
Our results in this double mutant suggest that the introduction
of the Large mutation does not interfere in the mechanism that
produces revertant fibers. Furthermore, in Dmdmdx/Largemyd mice
we also found the secondary deficiency of sarcoglycan proteins, as
observed through the analysis of δ-SG, confirming alterations in
the DGC. Alterations in the DGC have not been described in the
Largemyd model. Therefore, in our double-mutant model, the lack
of dystrophin was probably the most important determinant for
the destabilization of the sarcoglycan subcomplex.
Therapy in Dmdmdx/Largemyd mice with adipose stem cells
Stem-cell-based therapies for the repair and regeneration of
different tissues, including muscle, is a promising alternative for
the treatment of neuromuscular diseases. However, to assess the
success of stem cell therapy, we need markers to identify exogenous
proteins, indicating the presence of the injected cells in the animal
model, as well as functional monitoring to confirm any clinical
benefit. In general, animal models for only one mutation do not
adequately address these questions in therapeutic preclinical trials.
Due to the benign phenotype of Dmdmdx, it is difficult to monitor
clinical benefits from any therapeutic trial. Furthermore, although
Largemyd mice are a good functional model, LARGE protein
alterations are not easily identifiable in their muscle. Here, as a proof
of concept, we preliminarily evaluated the potential of our new
model to be used in stem cell transplantation. The homing,
retention and differentiation of systemically injected wild-type
mASCs was tested in a short time experiment. We observed that
the injected cells could reach the affected muscles, because we
identified the DNA sequence from the normal allele of the Large
dmm.biologists.org1172
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gene in the different muscles of the injected double-mutant animals.
Additionally, we could detect traces of dystrophin in those muscles.
In conclusion, our new Dmdmdx/Largemyd model is very useful
for stem cell replacement, or any other molecular or
pharmacological therapy studies, because we could trace the
injected cells/vector/DNA through both DNA and protein analysis.
The substantial weakness of these mice will also be very informative
to evaluate a functional benefit of these therapies. Additionally, it
is important to highlight that any future therapeutic trial must be
performed in a perfect window of time to give the appropriate
answer. More studies with a larger number of treated animals and
longer time frames are necessary to enhance the amount of retained
stem cells and to improve the amount of expressed muscle proteins,
leading to a better therapeutic effect.
MATERIALS AND METHODS
Mice
The two lineages of dystrophic mice, Dmdmdx and Largemyd, were
obtained from our animal facility, in the Human Genome Research
Center at University of São Paulo. All lines are available at The
Jackson Laboratory. The mice were kept under standard care
conditions that minimize stress and optimize breeding. All
experiments were approved by the Research Ethics Committee of
the Biosciences Institute, University of São Paulo, protocol
098/2009.
Parental lineages were: (1) C57BL/10ScSn-Dmdmdx/J (MGI:
1856328), also known as Dmdmdx, a model for DMD. This mouse
has a mild phenotype, retains a normal lifespan, and affected males
and females are both fertile (Bulfield et al., 1984; Dangain and
Vrbova, 1984). (2) B6C3Fe a/a-Largemyd/J (MGI: 1342270), also
known as Largemyd (Grewal and Hewitt, 2002) in the C57BL
background. The mutation underlying the myodystrophy
phenotype has been determined to be an intragenic deletion of
exons 5-7, causing a frameshift and a premature stop codon before
the first two catalytic domains in the glycosyltransferase LARGE
protein. Homozygous mice show abnormal skeletal muscle fiber
morphology, decreased body weight, postnatal growth retardation
and reduced fertility. The lineage is maintained through the
breeding of heterozygous animals.
For histopathological and protein studies, animals were
euthanized in a CO2 chamber, and tissues were collected and
processed for the different analyses. Muscle samples were obtained
from gastrocnemius biopsies, frozen in liquid nitrogen immediately
after removal, and stored at −70°C until use.
Production of double-mutants
For F1 production, Dmdmdx females were mated with Largemyd+/−
males. The F1 Dmdmdx/Largemyd+/− males were identified by
genotyping for the Large mutant allele (Browning et al., 2005), and
backcrossed to Dmdmdx females. In F2, both female and male
Dmdmdx/Largemyd+/− were selected and mated to obtain in F3 the
progeny homozygous for the Large mutation, i.e. the Dmdmdx/
Largemyd double mutants (Fig. 1).
Genotyping for the Large mutant and wild-type alleles
The presence of the pathogenic mutation in the studied animals
was tested by using multiplex polymerase chain reaction (PCR)
analysis for the wild-type and mutated alleles (Grewal et al., 2005).
DNA was prepared from mouse-tail tips (0.4-0.6 cm), precipitated
with isopropanol and used in a concentration of 50 ng per reaction.
For PCR amplification, the described set primers were used: the
wild-type 162 bp fragment was amplified with the primers: sense
5-GGCCGTGGTCCATAAGTTCAA-3 and antisense 5-
GGCATACGCCTCTGTGAAAAC-3, and the mutant allele of 421
bp was amplified simultaneously, using the primers sense 5-
ATCTCAGCTCCAAAGGGTGAAG-3 and antisense 5-GCCA -
ATGTAAAATGAGGGGAAA-3.
Both PCR products were amplified in a total volume of 25 μl in
the presence of 150 mM dNTPs, 20 pmol primer (each), 1.5 units
Taq DNA polymerase (Amersham) and 2.5 μl 10× buffer
(Amersham). Products were run in 2% agarose gels, stained with
ethidium bromide and photographed under UV illumination.
Magnetic resonance images
The MRI acquisitions were performed in one mouse of each strain
(Dmdmdx/Largemyd, Dmdmdx, Largemyd and C57BL) at 2 months of
age. The mice were anesthetized with intraperitoneal injection of
ketamine/xylazine (2:1, 1.5-2.5 μl/g body weight according to the
lineage). The images were acquired in a 2 T/30 cm superconducting
magnet (Oxford Instruments 85310HR, Abingdon, UK) interfaced
with a Bruker Avance AVIII console (Bruker-Biospin, Inc., Billerica,
MA) running PARAVISION 5.0, with a crossed-saddle
radiofrequency coil (Papoti, 2006). The sequence parameters were:
echo time (TE): 40 ms, repetition time (TR): 1500 ms, 4 averages,
slice thickness: 1.5 mm, spatial resolution: 0.176×0.176 mm2/pixel.
Histology and protein analysis
Muscle cryosections were stained with hematoxylin and eosin for
histopathological evaluation (Dubowitz and Sewry, 2007). For
immunofluorescence analyses, simple or double reactions were
done, as previously described (Vainzof et al., 1991). Briefly, four to
six cryostat sections were thawed on polylysine-coated slides and
air dried for 1 hour. The sections were incubated with primary
antibodies overnight at room temperature. The primary antibodies
used were: dystrophin-H-300 (Santa Cruz Biotechnology, Inc.), α-
2-laminin-4H8-2 (Santa Cruz Biotechnology, Inc.) and δ-
sarcoglycan (Nigro et al., 1996). Subsequently, sections were washed
three times with PBS, and incubated with secondary antibodies for
1 hour. After three additional washings, the sections were mounted
using Vectashield mounting product (Vector Laboratories; London,
UK) and analyzed under a Zeiss Axiophot microscope with
epifluorescence (Carl Zeiss, Oberkochen, Germany).
The same exposure time was used for registration of all reactions,
and image exposure time was standardized using the positive
normal control for each reaction/antibody/day. Digital pictures
were taken using the Axiovision 4.5 software (Carl Zeiss).
mASC isolation, expansion and injections
Subcutaneous adipose tissue of adult wild-type C57BL mice was
collected, washed with PBS containing 2.5% antibiotics [penicillin
and streptomycin (Gibco)] and dissociated with 0.075% collagenase
(Sigma) at 37°C for 30  minutes. The collagenase activity was
neutralized by DMEM/F12 (Dulbecco’s modified Eagle medium:
Nutrient Mixture F-12, Invitrogen) containing 10% FBS (fetal
bovine serum; Gibco). The preparation was centrifuged (1200 g,
5 minutes) and the cell pellet was plated in cell culture flasks in
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DMEM-F12 containing 20% FBS and 2% antibiotics [penicillin and
streptomycin (Gibco)]. Subsequently, the cultures were maintained
at 37°C in a CO2 incubator with 5% humidity. Every 72 hours, the
plated cells were washed with 1× PBS, to remove dead cells, and
replated when confluent. When the selected cells were
predominantly mASCs, they were characterized by flow cytometry,
and used for the injection protocol.
The cells were characterized by the expression of membrane
proteins that are specific to mASCs (Guava cytometer EasyCyte
System, Guava Technologies), and were positive for the markers
CD29 (97%), CD105 (86%), CD90 (99%), CD44 (99%), CD13 (85%)
and CD31 (80%), and negative for CD34 (4%) and CD45 (10%)
(antibodies from BD Biosciences Pharmingen).
The experiment was performed with three dystrophic Dmdmdx/
Largemyd mice available at the age of 2 months. Two animals
received three weekly repeated injections of 106 cells, via the caudal
vein, whereas one was injected on the same dates with PBS. All
three mice were functionally evaluated before and after starting
the injection experiment (in the 4th week), and euthanized for
molecular and histological studies.
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